All News

WHITEHOUSE STATION, N.J., April 27 -- Merck said today that the FDA has rejected the investigational Cox-2 inhibitor etoricoxib (Arcoxia) for marketing.

ANN ARBOR, Mich. -- Several genetic regions appear to contribute to the risk of developing type 2 diabetes, three research groups have found in a major collaborative effort.

BALTIMORE -- Neither naproxen (Aleve) nor celecoxib (Celebrex) reduced the risk of Alzheimer's disease, at least in the short term, investigators from the suspended ADAPT trial reported.

NEW YORK -- Some of the structural cells in the brain -- long thought to be passive onlookers as motor neurons die in amyotrophic lateral sclerosis -- are actually major players, according to two research groups.

BOSTON -- Despite new regulations governing physician-industry relationships, there has been no letup in the pursuit of high-prescribing physicians by pharmaceutical and other medical marketers, researchers here reported.

ANCHORAGE -- After responding well for three years to the heptavalent childhood pneumococcal vaccine, Native Alaskan children are falling ill from strains of Streptococcus pneumoniae not covered by the vaccine, according to the CDC.

BOSTON -- Neither abortion nor miscarriage contributes to the risk of breast cancer, according to a prospective observational study of more than 100,000 women.

BRADFORD, England -- Well-meaning physicians may unwittingly induce delirium in older patients when they prescribe medications such as antihistamines or sleep aids, according to a literature review.

ANCONA, Italy -- A five-drug postoperative chemotherapy regimen for gastric cancer that appeared promising in preliminary studies did not improve survival, researchers here reported.